10/21/2009

GlaxoSmithKline's Votrient has gained FDA clearance to treat a form of kidney cancer called advanced renal cell carcinoma. The decision comes after an FDA panel unanimously voted to endorse the once-daily drug for approval.

Full Story:
MarketWatch

Related Summaries